Ascentage Pharma: Ascentage Pharma (http://6855.HK) is a globally-focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B, and age-related diseases. The company focuses on developing therapeutics that inhibit protein-protein interactions to restore apoptosis, or programmed cell death. Ascentage Pharma has built a pipeline of eight clinical drug candidates, including a novel, highly potent Bcl-2/Bcl-xL inhibitor, as well as candidates aimed at IAP and MDM2-p53 pathways, and next-generation tyrosine kinase inhibitors. The company has been conducting 28 Phase I/II clinical trials to evaluate the eight drug candidates in the United States, Australia, and China.
Based in...
Clinical Stage
Phase l or ll
Disease Space
Anti-infectives, Antivirals, Oncology, Ophthalmology
9400 Key West Avenue, Suite 280
Rockville, MD 20850

Top 10 Holders of Ascentage Pharma Group International

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
The Vanguard Group, Inc. 1.50 3,102,000 0.00 Funds 9/30/20
China Asset Management (Hong Kong) Ltd. 0.30 612,600 0.00 Funds 6/30/20
GF Fund Management Co., Ltd. 0.19 400,000 0.00 Funds 6/30/20
China Southern Asset Management Co., Ltd. 0.02 31,900 0.00 Funds 6/30/20
Hang Seng Investment Management Ltd. 0.01 30,000 0.00 Funds 6/30/20
Bank of China Investment Management Co., Ltd. 0.01 15,000 0.00 Funds 6/30/20
Schroder Investment Management (Hong Kong) Ltd. 0.00 5,430 0.00 Funds 12/31/19
BlackRock Advisors LLC 0.00 2,500 0.00 Funds 8/31/20
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.